Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge

High doses become routine patient care even when they make patients so ill that they skip doses or stop taking the drugs. “There’s a gap in FDA’s authority that results in patients getting excess doses of a drug at excess costs,” says Dr. Mark Ratain.